News and Treatment Updates

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

AAML1831: A Phase III Trial Comparing Standard Induction Therapy With CPX-351 in De Novo Pediatric AML: A Report From the Children's Oncology Group

Original Publication Date
Article Source
External Web Content
Abstract Purpose The Children's Oncology Group phase III clinical trial AAML1831 (ClinicalTrials.gov identifier: NCT04293562) evaluated liposomal daunorubicin and cytarabine (CPX-351) versus standard daunorubicin/cytarabine (DA) induction therapy in children and young adults with…

Patient and Caregiver Involvement With Prior Authorization and Care Delivery and Delays

Original Publication Date
Article Source
External Web Content
Introduction Payers employ health care utilization–management strategies, including prior authorization (PA), to limit costs and promote evidence-based, guideline-concordant care. However, PA may be inconsistently applied and associated with patient confusion and frustration.1-3…

Mapping Human Bone Marrow Yields New Tool, Insights on Blood Cancer

Original Publication Date
Article Source
External Web Content
Weill Cornell Medicine investigators have developed a new AI-based method to assess patients with a form of blood cancer called myelodysplastic neoplasms. The method, published June 30 in Leukemia, compares the physical locations and morphometric (size and shape) characteristics…

Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study 

Original Publication Date
Article Source
External Web Content
ABSTRACT The RACE study (NCT02009747) compared horse antithymocyte globulin (hATG) plus cyclosporine A (CsA) ± eltrombopag as initial immunosuppressive treatment (IST) for severe aplastic anemia. Here we report the final 2-year analysis of this prospective randomized phase III…

TA-TMA and GVHD are distinct consequences of endothelial injury: a MIDAS consortium study

Original Publication Date
Article Source
External Web Content
Key Points Posttransplant cyclophosphamide significantly reduced GVHD incidence but not TA-TMA incidence, which predated acute GVHD in ∼50% of cases. TA-TMA biomarker soluble C5b-9 was not significant in adults; pre-HCT serum creatinine, placental growth factor, and day +28 ST2…

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.

We Recommend

For Patients and Families